For 34-year-old Daniel Kerr, sport is life. The talented Perth-born Australian rules footballer, best known for playing 220 games for the West Coast Eagles between 2001 and 2013, is no stranger to pain for gain.
90+ reasons to smile
What happens when you bring 90+ expert dentistry and maxillofacial surgeon’s together in a room to unpack the burgeoning world of collagen membrane technology and digital dentistry?
Channel 7 | Ortho-ATIâ„¢ Feature Story
Channel 7 News Perth has showcased Orthocell’s successful tendon treatment therapy for AFL star Daniel Kerr.
Orthocell Board Member Heralded For Lifelong Contribution To Orthopaedics
Orthocell Ltd (ASX: OCC) is today celebrating the lifelong achievements of Professor Lars Lidgren, a Swedish surgeon, researcher, entrepreneur and Orthocell board member, who has been awarded an honorary fellowship by the American College of Surgeons (ACS).
Video | Channel 9 News Report – Ortho-ATIâ„¢ – June 2018
Channel 9 News has featured Orthocell’s Ortho-ATIâ„¢ as part of its nightly news coverage.
Move over miners, Perth’s next hard cell is bio-manufacturers
Orthocell has been featured in the Weekend Australian this week as one of two Perth companies transforming the state’s economic reliance on mining.
Orthocell highlights its novel ability to treat tennis elbow
Positive results from Orthocell’s study into its novel tendon cell therapy treatment for tennis elbow have been featured in Small Caps.Â
Orthocell looks forward to strong European market after successful clinical study
Small Caps has reported on a successful clinical study showing our CelGroâ„¢ medical device improves dental bone regeneration.
Orthocell secures Canadian patent rights for tendon regeneration
News that Orthocell has been granted a key Canadian patent for our Ortho-ATI product has been published in Small Caps.
Video | CommSec Interview – December 2017
Orthcell CEO and Managing Director, Paul Anderson, speaks with CommSec’s Tom Piotrowski about the company’s two key products, its recently received CE Mark approval for its CelGroâ„¢ product and its plans for commercialisation in FY18.